Vadastuximab talirine
As of the edition of 20 October 2026, Vadastuximab talirine is an antibody drug conjugate: went quiet in 2018; acts on CD33.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2018
- Kind
- Antibody drug conjugate
- Registered trials
- 5, 3 stopped early
- Disease areas
- Blood and lymph; Cancer
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CD33 | Myeloid cell surface antigen CD33 | P20138 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 2 | 0 | 0 | 2 |
| Phase 3 | 1 | 0 | 0 | 1 |
| All trials | 5 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Pfizer | Lead sponsor of trials | 2013 to now |